Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qbrexza in axillary hyperhidrosis (ATMOS-2)
NCT02530294Phase 3Completed
- Sponsor
- Journey Medical Corporation
- Start
- Aug 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of glycopyrronium in primary axillary hyperhidrosis (PAH), sponsored by Journey Medical Corporation. Started Aug 2015; status: completed.
02
Drugs
glycopyrronium
03
Conditions
primary axillary hyperhidrosis (PAH)
Beyond the preview
Go deeper on NCT02530294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530294.